You are viewing the site in preview mode
Skip to main content
|
Adverse event
|
PF group [cases (%)]
|
TPF group [cases (%)]
|
P value
|
|---|
|
Grade 0–2
|
Grade 3–4
|
Grade 0–2
|
Grade 3–4
|
|---|
|
Neutropenia
|
207 (70.4)
|
87 (29.6)
|
176 (59.9)
|
118 (40.1)
|
0.009
|
|
Anemia
|
275 (93.5)
|
19 (6.5)
|
286 (97.3)
|
8 (2.7)
|
0.047
|
|
Thrombocytopenia
|
268 (91.2)
|
26 (8.8)
|
284 (96.6)
|
10 (3.4)
|
0.009
|
|
Liver injury
|
291 (99.0)
|
3 (1.0)
|
292 (99.3)
|
2 (0.7)
|
1.000
|
|
Kidney injury
|
294 (100)
|
0 (0)
|
294 (100)
|
0 (0)
|
1.000
|
|
Nausea/vomiting
|
114 (38.8)
|
180 (61.2)
|
151 (51.4)
|
143 (48.6)
|
0.003
|
|
Any of the above
|
109 (37.0)
|
185 (63.0)
|
83 (28.2)
|
211 (71.8)
|
0.028
|
- TPF taxane, cisplatin and 5-fluorouracil, PF cisplatin and 5-fluorouracil. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria, version 4.0
